Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
CROI 2015: PrEP Provides 86% Protection in 2 Studies [VIDEO]
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 05 March 2015 00:00
- Written by Gregory Fowler
Among the most eagerly anticipated and well received news at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle were a pair of reports showing that Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, or PrEP, taken either daily or before and after sex, reduced the likelihood of HIV infection by 86%. In both studies, no one who took PrEP consistently became infected.
CROI 2015: Maraviroc Levels in Vaginal and Rectal Tissues May Not Be High Enough for PrEP
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Monday, 02 March 2015 00:00
- Written by Liz Highleyman
Levels of the HIV entry inhibitor maraviroc (Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection against HIV in a laboratory study, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Multiple doses, however, could still potentially be effective for pre-exposure prophylaxis, or PrEP.
CROI 2015: PrEP Stops 86% of HIV Infections in PROUD Study
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 24 February 2015 00:00
- Written by Gus Cairns
A study of pre-exposure prophylaxis (PrEP), the English PROUD study, demonstrated the highest effectiveness yet seen for this method of HIV prevention, the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle heard today. The effectiveness was 86%; for every 20 infections that might have occurred in participants, 17 were stopped by PrEP.
CROI 2015: PrEP Use Rising in San Francisco, but Scale-Up Could Cut New Infections
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 25 February 2015 00:00
- Written by Liz Highleyman
Use of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, better known as PrEP, is increasing in San Francisco, but it is still only reaching about one-third of people who could benefit, and wider use could reduce new HIV infections by 70%, according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.
CROI 2015: On-Demand PrEP Prevents 86% of HIV Infections in Ipergay
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 24 February 2015 00:00
- Written by Gus Cairns
A French and Canadian study of pre-exposure prophylaxis (PrEP) presented today at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle found that the HIV infection rate for participants taking an intermittent PrEP regimen was 86% lower than for people taking an inactive placebo. Extraordinarily, this is exactly the same level of effectiveness that was demonstrated in the English PROUD study, whose outcomes were presented 15 minutes before Ipergay. Ipergay is a very different study than PROUD and it is encouraging that 2 different ways of taking PrEP have both proved effective in gay men, at least in a western European context.
Web Design and Development by